INTRODUCTION {#s1}
============

Breast Cancer susceptibility genes 1&2 (BRCA1&2) are tumor suppressor genes, involved in DNA-repair and cell cycling \[[@R1]\]. BRCA1&2 mutations are known to increase the risk for breast and ovarian cancer among females. There is also evidence of increased risk for prostate cancer and others among males \[[@R2]--[@R4]\].

Limited data suggest that BRCA-mutations are also associated with increased risk for non-cancer related mortality. Mai *et al.* \[[@R5]\]. used an Ashkenazi Jewish cohort from Washington DC to estimate the effect of BRCA1&2 mutations on mortality. They have demonstrated that life expectancy was shorter among BRCA-mutation carriers (5.7 years lower for women, 3.7 for men) compared to age-matched general population.

Physiologically, several common pathways are emerging that link DNA-instability with both cancer and cardiovascular disease. Shukla *et al*. \[[@R6]\] demonstrated a novel role for BRCA1 as a gatekeeper of cardiac-function and survival after ischemia. They showed that in mice, response to stress was deficient in cardiomyocytes lacking BRCA1. These mice had impaired DNA repair mechanisms resulting in activated apoptotic p53-mediated signaling. These pathways are implicated in many cancers as well \[[@R7]--[@R9]\]. Similar findings were reported for BRCA2-mutations \[[@R10]\]. In patients with Ataxia-Telangiectasia, a genetic disease with a similar DNA-repair defect, there is evidence of increased risk for premature atherosclerosis \[[@R11]--[@R15]\].

One of the earliest manifestations of cardiovascular impairment is "endothelial-dysfunction" \[[@R16]--[@R19]\]. Cardiovascular risk factors activate pro-oxidative genes in the endothelium. Thus, generating reactive oxygen species (ROS) leading to release of transcriptional and growth factors, pro-inflammatory cytokines, chemo-attractant substances, and adhesion molecules \[[@R15]--[@R18], [@R20]\].

The primary objective of this study was to compare the endothelial function of positive and negative BRCA-mutation carriers. Furthermore we aimed to explorer possible pathophysiologic pathways that may mediate BRCA's effect on the cardiovascular system and the vascular endothelium.

RESULTS {#s2}
=======

Between 08/07/2015 and 24/07/2017 82 participants (53 BRCA positive and 29 BRCA negative mutation-carriers) were enrolled in the study and underwent genetic testing and endothelial assessment. Baseline characteristics of the participants according to BRCA-mutation status are shown in [Table 1](#T1){ref-type="table"}. Both groups were similar in terms of age, cardiovascular risk factors, exercise habits, lipid profile and pituitary hormone levels. The mutation positive participants were less likely to be active smokers and more likely to be former smokers then the mutation negative participants. However, there was no difference in pack years between the two groups.

###### Baseline characteristics according to BRCA mutation status

                                           BRCA negative (*n* = 29)   BRCA positive (*n* = 53)   *p*-val
  ---------------------------------------- -------------------------- -------------------------- ---------
  Age, years (avg ± SD)                    40.71 ± 6.43               39.09 ± 5.41               0.301
  BMI (avg ± SD)                           26.23 ± 4.55               26.48 ± 4.05               0.832
  Smoking                                                                                        0.047
  Never smoked, *N* (%)                    13 (72.2%)                 40 (75.5%)                 
  Former smoker, *N* (%)                   2 (11.1%)                  12 (22.65)                 
  Active smoker, *N* (%)                   3 (16.7%)                  1 (1.9%)                   
  PY (median, IQR)                         0 \[0,0.38\]               0 \[0,0\]                  0.351
  Regular exercise, *N* (%)                12 (66.7%)                 32 (60.45)                 0.674
  Exercise days/week, (median, IQR)        2.5 \[0,3.63\]             2 \[0,3\]                  0.157
  DM, *N* (%)                              0 (0%)                     1 (1.9%)                   1.000
  HTN, *N* (%)                             3 (16.7%)                  2 (3.8%)                   0.099
  TSH, mlU/L (avg ± SD)                    1.89 ± 1.60                1.74 ± 0.72                0.582
  FSH, mlU/ml (avg ± SD)                   4.17 ± 2.46                4.32 ± 3.12                0.860
  LH, mlU/ml (avg ± SD)                    4.08 ± 2.27                3.45 ± 1.94                0.260
  Prolactin, mcg/l (avg ± SD)              6.58 ± 2.45                5.31 ± 1.94                0.130
  Free androgen index (avg ± SD)           45.86 ± 11.84              43.53 ± 14.82              0.549
  Testosterone- total, nmol/L (avg ± SD)   18.67 ± 7.17               16.12 ± 5.91               0.142
  SHBG, nmol/L (avg ± SD)                  42.85 ± 20.97              39.46 ± 15.91              0.477
  PSA, ng/ml (avg ± SD)                    0.69 ± 0.28                0.6612 ± 0.28              0.675
  Cholesterol, mg/dl (avg ± SD)            197.94 ± 38.87             189.63 ± 40.56             0.452
  Triglycerides, mg/dl (avg ± SD)          116.78 ± 46.38             146.39 ± 89.24             0.184
  HDL, mg/dl (avg ± SD)                    46.39 ± 8.41               48.18 ± 14.28              0.619
  LDL, mg/dl (avg ± SD)                    128.11 ± 35.22             112.98 ± 38.10             0.147

Abbreviations: BMI, body mass index; DM, diabetes mellitus; FSH, follicle stimulating hormone; HDL, high density lipoprotein; HTN, hypertension; LDL, low density lipoprotein; LH, luteinizing hormone; PY, pack years; PSA, prostate specific antigen; SHBG, sex hormone binding globulin; TSH, thyroid stimulating hormone.

Endothelial function assessment {#s2_1}
-------------------------------

There was no difference in endothelial function, as assessed by EndoPAT™. The mean LnRHI was 0.717 ± 0.28 in mutation-negative vs. 0.719 ± 0.27 in mutation-positive participants (*p*-value 0.976).

EPCs assessments {#s2_2}
----------------

### Quantitative assessment ([Figure 1](#F1){ref-type="fig"}) {#s2_2_1}

![Quantitative assessment of EPCs in BRCA positive carriers and negative carriers.\
Boxplots comparing the fraction of EPCs as a proportion of total PMNC between BRCA positive (Orange) and Negative (Blue) participants. (**A**) EPCs are identified as CD34+/VEGF+ cells by flow cytometry. (**B**) EPCs are identified as CD133+/VEGF+ cells by flow cytometry.](oncotarget-10-5041-g001){#F1}

### Unadjusted analysis {#s2_2_2}

The fraction of EPC (out of total PMNC) was higher in mutation positive participants either when assessed by CD34+/VEGF+ (median 6.78\[1.96,14.48\]% vs. 1.46\[0.65,6.18\]%, *p* \< 0.001, [Figure 1A](#F1){ref-type="fig"}) or CD 133+/VEGF+ (median 7.17\[1.70,16.69\]% vs. 1.54\[0.85,5.10\]%, *p* \< 0.001, [Figure 1B](#F1){ref-type="fig"}), representative FACS data for control and mutation positive carrier patients are shown in [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}.

Multivariate adjusted analysis {#s2_3}
------------------------------

Using a linear regression model that included age, BMI, smoking status, regular exercise, LDL, HDL, TG, total cholesterol and BRCA mutation status as covariates, BRCA positive-mutation status was associated with an increase of 6.02(SE 2.90)% in CD133+/VEGF+ cells (*P* = 0.024) and of 4.72 (SE 2.49)% in CD34+/VEGF+ cells (*p* = 0.058).

Qualitative assessment {#s2_4}
----------------------

There was no difference in levels of MTT and CFU between BRCA positive and negative-mutation participants, with either unadjusted analysis or multivariate adjusted linear regression ([Figure 2A](#F2){ref-type="fig"}, [2B](#F2){ref-type="fig"} and [Table 2](#T2){ref-type="table"}).

![Assessment of EPCs activity, markers of endothelial damage and stimulation for EPCs production in BRCA positive carriers and negative carriers.\
Boxplots comparing the values of the MTT essay (**A**), CFU/Field (**B**), CECS X 10^4^ (**C**), IGF (**D**), VEGF (**E**) and SDF-1 (**F**) between BRCA positive (Orange) and Negative (Blue) participants.](oncotarget-10-5041-g002){#F2}

###### Association of BRCA mutation status and additional EPC markers

                 Unadjusted analysis   Adjusted analysis^\*^                             
  -------------- --------------------- ----------------------- ------- -------- -------- -------
  CECS X 10^4^   1.25 (1,2)            2 (1,2.25)              0.460   −0.752   0.410    0.188
  MTT            0.15 (0.99,0.20)      0.12 (0.10,0.14)        0.239   0.008    0.25     0.753
  VEGF           461 (140,821)         565 (226,816)           0.539   −109.9   133.70   0.439
  IGF            5.06 (4.63,5.80)      5.08 (4.80,6.22)        0.491   0.10     0.333    0.977
  CFU            2 (1,3)               3 (2,3)                 0.463   −0.336   0.589    0.574

Values are presented as median (IQR).

Abbreviations: BRCA, breast cancer susceptibility genes; CECS, circulating endothelial cells; VEGF, vascular endothelial growth factor; IGF, insulin like growth factor; CFU, colony forming unit; MTT, 3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide.

Endothelial damage assessment {#s2_5}
-----------------------------

There was no difference in levels of CECX10^4^ between BRCA positive and negative-mutation participants, with either unadjusted analysis or multivariate adjusted linear regression ([Figure 2C](#F2){ref-type="fig"} and [Table 2](#T2){ref-type="table"}).

Stimulation for EPCs production {#s2_6}
-------------------------------

There was no difference in IGF, VEGF or SDF-1 alpha between BRCA positive and negative-mutation participants, with either unadjusted analysis or multivariate adjusted linear regression ([Figure 2D](#F2){ref-type="fig"}--[2F](#F2){ref-type="fig"} and [Table 2](#T2){ref-type="table"}).

Other biomarkers {#s2_7}
----------------

All participants had hsTnT levels that were below 13ng/ml so no comparison between mutation positive and negative participants was performed.

The results of CRP, D-dimer and NTproBNP levels in BRCA-mutation positive vs. negative participants are shown in [Figure 3A](#F3){ref-type="fig"}--[3C](#F3){ref-type="fig"} and [Table 3](#T3){ref-type="table"}.

![Assessment of inflammation, coagulation and natriuretic peptides in BRCA positive carriers and negative carriers.\
Boxplots comparing the values CRP (**A**), D-Dimer (**B**) and NTproBNP (**C**) between BRCA positive (Orange) and Negative (Blue) participants.](oncotarget-10-5041-g003){#F3}

###### Association of BRCA mutation status and cardiac biomarkers

                                   Unadjusted analysis   Adjusted analysis\*                            
  -------------------------------- --------------------- --------------------- ------- -------- ------- -------
  CRP, mg/l (median, IQR)          0.21 (0.06,0.47)      0.24 (0.06,42)        252     0.552    0.535   0.308
  D-dimer, ng/ml (median, IQR)     164 (110,262)         173 (117,342)         0.628   −54.33   65.02   0.404
  NTpro-BNP, pg/ml (median, IQR)   17 (13,25)            23 (14,32)            0.153   −17.65   9.14    0.189

^\*^Adjusted for age, BMI, smoking status, regular exercise, LDL, HDL, TG, total cholesterol.

Abbreviations: BRCA, Breast Cancer susceptibility genes; CRP, C-reactive protein; NTproBNP, N-terminal pro b-type Natriuretic Peptide.

There was no significant difference in the levels of CRP, D-dimer or NT-proBNP with either unadjusted (*p* = 0.252, *p* = 0.628 and *p* = 0.153, respectively) or multivariate adjusted analysis using a linear regression model (*p* = 0.308, *p* = 0.404 and *p* = 0.189, respectively) between mutation-positive and negative participants.

DISCUSSION {#s3}
==========

The major finding of our study is that male BRCA1&2 positive mutation-carriers show a significantly increased fraction of EPCs, compared to age matched non-carriers. BRCA1&2 mutation status was not associated with a significant differences in endothelial function, overall quantity or viability of endothelial cells or levels of cardiovascular biomarkers (VEGF, hsTnt, NTproBNP D-dimer) and inflammation biomarker (CRP).

Recently, it was shown that DNA-damage and premature vascular aging have a significant role in endothelial-dysfunction \[[@R21]--[@R23]\]. Risk factors, such as smoking and diabetes leads to increase in ROS molecules within the atherosclerotic plaque, and induce DNA damage. Genomic instability, such as occurs in BRCA-mutations, can promote endothelial dysfunction and/or cause cell cycle arrest, apoptosis and senescence \[[@R24]--[@R26]\].

The hallmarks of BRCA-mutations are genetic instability and DNA-fragmentation thus we hypothesize a link between the two. In women, due to the combination of a high prevalence of cancers at a young age, and cardiovascular diseases at an older age, the effect of BRCA1&2-mutations on cardiovascular morbidity and mortality is difficult to evaluate. However, they might be exposed to increased cardiovascular risk due to exposure to cardiotoxic treatments such as chemotherapy, chest radiotherapy, and/or HER2 directed therapies \[[@R27]\].

In men however, BRCA1&2 related cancers are less prevalent and have better prognosis. Usually, those cancers manifest at older ages than the initial appearances of cardiovascular diseases. Hence, BRCA1&2 related cardiovascular morbidity is important factor for prognosis.

As far as we know, this study is the first to examine possible mechanisms for BRCA1&2's effect on the endothelial system.

Endothelial progenitor cells (EPCs) regulate vascular integrity by promoting renewal of endothelial cells following injury \[[@R24]--[@R26]\]. Specifically, levels of circulating EPCs are lower among patients with chronic stable coronary artery disease (CAD) or with cardiovascular risk factors compared to controls \[[@R18]\]. Moreover, low EPC levels may predict cardiovascular-related events and death from cardiovascular causes \[[@R24]\].

EPCs express cell-surface antigens including CD133, CD34 and vascular endothelial growth factor receptor-2 (VEGFR-2) \[[@R28]\]. EPCs levels, contrary to measuring single serum marker may better estimate the overall function or dysfunction of the endothelial \[[@R29], [@R30]\]. Our data demonstrates that BRCA1&2-mutations are associated with higher EPC count. Thus, suggesting a pathophysiological link between DNA-repair damage and the endothelial system.

The gold standard to quantify endothelial function is to measure coronary epicardial vaso-reactivity during coronary angiography. It is an invasive procedure that requires specialized equipment and personnel and makes it therefore less suitable in a research setting. The EndoPAT2000 is a non-invasive device that is used to assess endothelial function \[[@R31]\]. We could not find a difference in endothelial function (assessed by EndoPAT), or evidence for endothelial damage (assessed by CECs) according to BRCA1&2-mutations status. We only included subjects younger than 50 years-old. It is possible that at such a young age the BRCA affect is subclinical and may only be realized at an older age.

Although BRCA1&2-mutation carriers had a higher quantity of EPCs then non-carries, there was no difference in the functionality of those cells (assessed by CFU and MTT essay). Similarly, no significant difference was found in factors that stimulate EPCs production (IGF, VEGF) or EPC incorporation into endothelial damage sights (SDF-1 alpha). These results suggest that the difference in EPCs quantity occur due to higher proliferation rates in mutation carriers then in the non-carriers.

Considering all these findings, our proposed hypothesis is that BRCA germline mutations cause an increased damage to endothelial tissue. To compensate there is an increase production of EPCs. This is supported by other reports demonstrating that BRCA is associated with premature ovarian failure and accelerated aging \[[@R32]--[@R34]\].

Our study has several limitations. First, our sample size was limited since we used a population that was referred for genetic screening. Second, to avoid bias we only included healthy young males. Therefore functional, clinical differences were not demonstrated. One of the strengths' of our study was the comprehensive testing of many different aspects of endothelial function. We have found that even in this young cohort without comorbidities the endothelial system is compromised. Moreover, our EPC results were consistent and robust even after multivariate adjustment.

This is one of the first studies to demonstrate a meaningful link between cancer-genes and endothelial-function. Personalized early primary prevention and screening in BRCA1&2-carriers, may reduce the morbidity and mortality associated with cardiovascular disease \[[@R35], [@R36]\]. Unveiling the physiological mechanism leading to the association between endothelial function and BRCA may in the future lead to novel discoveries of prevention and treatment of both cancer and cardiovascular disease. It may also strengthen the evidence to suggest that cancer is part of a larger metabolic-disease.

MATERIALS AND METHODS {#s4}
=====================

Study design {#s4_1}
------------

This was a prospective cohort study designed to examine the endothelial-function of young healthy male cohort of BRCA1&2 germline-mutation carriers. Study included male participants that were referred for BRCA-mutation screening due to their family history cancers and BRCA-mutations. Inclusion criteria were: males, age 18-50 years old, definitive results of genetic testing for BRCA-mutation, and willing to sign an informed consent. Exclusion criteria were: history of myocardial infarction, ischemic or hemorrhagic cerebrovascular conditions, arterial embolic or thrombotic events, ischemic heart disease, prior coronary artery revascularization (percutaneous or surgical procedures), or peripheral vascular disease (e. g. claudication, prior vascular surgery/intervention).

Outcomes {#s4_2}
--------

### Primary outcomes {#s4_2_1}

-   Comparison of ∆RHI between BRCA1&2 positive and negative mutation-carriers.

-   Difference in fraction of CD34+VEGF+/CD133+VEGF+ cells between BRCA1&2 positive and negative mutation-carriers.

### Secondary outcomes {#s4_2_2}

-   Differences in cardiovascular biomarkers between BRCA positive and negative mutation-carriers.

### BRCA status assessment {#s4_2_3}

Genetic testing was done for all known 15 founder mutations in Jews, i. e., \"The Jewish panel\" \[[@R37]--[@R40]\] in BRCA1 (ONIM: 113705) and BRCA2 (ONIM: 600185) genes ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Complete DNA-sequencing for all BRCA-mutations was not done due to the fact that these founder mutations constitute 95% of all mutations in Jews \[[@R37]--[@R40]\]. The search for mutations was done by Nano-Fluidic Chip 96.96CS (Dynamic Array™ IFC for Genotyping) using the Biomark HD System™ by Fluidigm.

### Assessment of endothelial function {#s4_2_4}

We used a comprehensive approach to study the endothelial-function with physiological and laboratory assessments. All tests were performed blinded to mutation status:

1\. *The Endo-PAT2000 (Itamar Medical Ltd, Keisariya, Israel) -* Endo-PAT2000 is a non-invasive device that measures changes in PAT (Peripheral Arterial Tone) before and after hyperemic response (occluding blood flow through the brachial artery for 5 minutes using an inflatable cuff) \[[@R41]\]. PAT change ratio is normalized to measurements from the contra-lateral arm, which serves as control for non-endothelial dependent systemic effects. The normalized value is termed reactive hyperemia index (RHI) \[[@R42]\]. RHI measure was shown to reflect NO-bioavailability and to correlate with endothelial vasodilator function in coronary artery \[[@R43], [@R44]\]. RHI value is reduced in patients with established cardiovascular disease and considered to be a predictor for cardiovascular clinical outcomes \[[@R45], [@R46]\].

2\. *Endothelial Progenitor Cells (EPCs) -* are early stem cells that play an important role in the regeneration of the endothelial lining of blood vessels.

a. Quantitative assessment of EPCs {#s4_3}
----------------------------------

### Isolation of mononuclear cells {#s4_3_1}

Samples were centrifuged using Ficoll density gradient centrifugation. Peripheral mononuclear cells (PMNCs) were isolated and washed with phosphate-buffered saline after red cell lysis.

### Flow cytometry {#s4_3_2}

We incubated PMNCs with monoclonal antibodies for FITC labelled VEGFR-2 (R&D, Minneapolis, USA), CD45-CYT5.5 (Dako, Denmark), and either CD133 (PE-labelled), or CD34 (PE-labelled, Miltenyi Biotech, Auburn, CA, USA). Antibodies with identical isotype were used as controls. Following incubation, we washed the cells with phosphate-buffered saline and analyzed by flow cytometer (FACSCalibur, Becton Dickinson) as described before \[[@R47]\]. Each analysis included 100,000 events after selection for CD45-positive cells (including low-intensity CD45+ cells) and exclusion of debris. In the next step, gated CD34 or CD133-positive cells were examined for the expression of VEGFR-2. Results are presented as the percentage of PMNCs co-expressing VEGF+/CD133+, or VEGF+/CD34+. Analyses were performed in duplicates.

b. Functional assessment of endothelial progenitor cells {#s4_4}
--------------------------------------------------------

### Colony forming unit (CFU) assay {#s4_4_1}

We re-suspended isolated PMNCs with Medium 199 (Invitrogen, Carlsbad, CA, USA), supplemented with 20% fetal calf serum (Gibco BRL Life Tech, Gaithersburg, MD, USA). Then, cells were plated on six-well plates coated with human fibronectin (4 × 10^6^ cells per well). After 7 days, we counted the EPCs colonies. EPC colony was defined as a cluster of at least 100 flat cells surrounding a cluster of rounded cells \[[@R48]\]. Results are displayed as mean number of CFUs per field.

### MTT assay {#s4_4_2}

MTT (3-\[4,5-dimethylthiazol-2-yl\]-2,5-diphenyl tetrazolium bromide) measures mitochondrial activity in living cells and used to evaluate viability of cultured cells. The assay was performed as previously described \[[@R47], [@R49]\]. After 7 days of culture, We added 1 mg/ml MTT (Sigma, St. Louis, USA) to the EPCs medium, and incubated for additional 3-4 hours. After incubation, the medium was removed and the cells were solubilized in isopropanol. The amount of dye, which was released from the cells and correlated to the number of living cells, was measured with a spectrophotometer at 570nm and subtracted background at 690nm. An increase in the number of viable cells results in an increase in the amount of MTT formed and, therefore, in absorbance. Results were corrected for the number of EPC CFUs in each group.

Assessment of endothelial damage {#s4_5}
--------------------------------

### Evaluation of circulating endothelial cells (CECs) {#s4_5_1}

Detection and quantification of CECs were performed using monodispersed magnetizable particles (Dynabeads CELLection Pan Mouse IgG kit; Invitrogen, Carlsbad, CA, USA) as previously described \[[@R50], [@R51]\]. Typically, 100 ml of bead suspension was noncovalently coated with 1.5 mg/ml of anti CD 146 (Novus Biologicals, Littleton, CO, USA, <http://www.novusbio.com>), an endothelial cell-specific monoclonal antibody. Beads and target cells were incubated for 1.5 h at 4° C on a rotator. Separation of beads and rosetted cells from the blood samples required a minimum of a 1min exposure to the magnet. Three washes were performed in this device to completely remove nonrosetted cells. After the third wash, rosetted cells were recovered in a 50-μl solution of acridine orange (a vital fluorescent dye at final concentration of 5 μg/ml in PBS), and observations were made in a hemacytometer under both white and fluorescent blue excitation using fluorescence microscopy.

### Assessment of chemokine/ growth factors in the plasma {#s4_5_2}

Plasma samples were stored at −70° C and later evaluated for vascular endothelial growth factor (VEGF), Insulin-like Growth Factor (IGF) and Stromal Cell-Derived Factor 1 (SDF-1) alpha, using ELISA assay. Kits were used according to the manufacturer's instructions (RayBiotech, Inc).

### Assessment of cardiovascular biomarkers {#s4_5_3}

Four biomarkers associated with different pathophysiologic pathways that affect the cardiovascular system were measured: High sensitive Troponin T (hsTnT) -- to assess myocardial injury, C Reactive-Protein (CRP) -- to assess inflammation, D-dimer -- to assess activation of the coagulation system, N-terminal pro-brain natriuretic peptide (NTproBNP) -- to assess myocardial strain. All assays were performed by ELISA, according to manufacturers' instructions.

Statistical analysis {#s4_6}
--------------------

Baseline characteristics are reported as numbers and percentages for categorical variables, and means ±SD or as medians (interquartile range) for continuous variables as appropriate. The characteristics were compared between BRCA-carriers and controls using the paired *t*-test or the Mann-Whitney *U*-test for continuous variables as appropriate, and Fisher's exact test for categorical variables.

Outcome measures are reported as means ± SD or as medians (interquartile range) as appropriate and were compared between BRCA carriers and controls using the paired *t*-test or the Mann-Whitney *U*-test as appropriate.

In addition, we performed an adjusted analysis by fitting a linear regression model for prediction of each outcome measure that included all relevant baseline characteristics as well as BRCA1&2-mutation status.

Sample size calculation {#s4_7}
-----------------------

Our primary outcome was RHI (a continuous variable). Previous studies have shown that endothelial function (assessed by RHI) was normally distributed with a standard deviation of 0.42 and that a clinically meaningful difference in endothelial function is ΔLnRHI of 0.26 \[[@R31]\]. Based on these assumptions, in order to have an 80% power to detect a clinically significant difference in RHI at a confidence level of 95%, a sample size of 82 patients was required. Allowing for 10% attrition of recruited patients, we aimed to reach a sample size of 90 patients. The actual sample size was 82 patients.

Ethical aspects, consent and confidentiality {#s4_8}
--------------------------------------------

The study was approved by the Rabin Medical-Center institutional ethics review board, in accordance to the Declaration of Helsinki. All participants received detailed verbal and printed information about the study, and signed a written informed consent form before enrollment in the study.
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